THE USE OF THE USE OF ANTITUBERCULOSIS DRUGS (A ANTITUBERCULOSIS DRUGS (ATD) TODAY

J. Rašić ,
J. Rašić

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

S. Janićijević-Hudomal ,
S. Janićijević-Hudomal

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

D. Radišić ,
D. Radišić

Internal clinic, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

Z. Bukumirić ,
Z. Bukumirić

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

Z. Stanojević
Z. Stanojević

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

Published: 01.12.2006.

Volume 34, Issue 2 (2006)

pp. 63-68;

https://doi.org/10.70949/pramed200602159R

Abstract

The World Health Organization (WHO) declared tuberculosis (TB) a global emergensy in recognition of its growing importance as public health problem. In response to this situation WHO in 1990 was developed new strategy and framework for effective TB control, wich was called „DOTS“. The aims of treatment of TB are: to cure the pation of TB, to prevent death from active TB or its late effects, to prevent relapse of TB, to decrease transmission of TB to others, and to prevent
the development of acqured drug resistance. Antituberculosis drugs (ATD) are antibiotics and synthetic drugs used in the
treatment of tuberculosis and other deases caused by microorganisms of the genus Mycobacterium. The essential ATD are:
isoniazid (H), rifampicin (R), pyrazinamid (Z), streptomycin (S), ethambutol (E), and thioacetazone (T). The reserve ATD
are: amikacin (Am), kanamycin (Km), capreomycin (Cm), ciprofloxacin (Cx), ofloksacin (O), cycloserine (Cs), ethionamide (Et), protionamide (Pt), and p-aminosalycilic acid (PAS). The regimen recommended for each patient depends on the
diagnostic category for each patient. There are several possible regimens. ATB treatment regimens consists of two phases:
an initial phase and a continuation phase

Keywords

References

1.
T.L P. Tuberculosis. JAMA. 291(1266).
2.
K. T, T. T, T. S, G. A, A. K, L. K, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 345:170–4.
3.
McCarthy M. Experts see progress in fight against tuberculosis. Lancet. 359(9322).
4.
P.G. S, K. F, J. P, E. A, E. R, G. R, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 359(9322):1980–9.
5.
T.L P. Timebomb: The global epidemic of multi-drug resistant tuberculosis. JAMA. 287:780–1.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by